MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd. (IPA), reports developments in Bio-Native AI, biologics discovery, and AI-driven drug development. Company updates focus on the HYFT® technology stack and the LensAI™ platform, which combine computational analysis with wet-lab validation for epitope mapping, de novo molecular design, in silico vaccine exploration, immunogenicity screening, and population-scale biologics analytics.
Recurring news also covers earnings releases, platform commercialization, partnership and customer activity, and portfolio initiatives such as B Cell Llama™ nanobody discovery and dengue vaccine research. Corporate updates include the transition from the ImmunoPrecise brand to MindWalk, the Nasdaq ticker change to HYFT, and portfolio refinements such as the divestiture of the Netherlands antibody-discovery operations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.